180 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 … the resource intensive, late stage istaroxime program advanced by a larger company, by adding the innovative aPKCi inhibitor platform to our early
8-K
EX-99.1
y3uzz3v35 yep8m24
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
8-K
EX-99.1
et55044o7
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.2
1vz0a0 wl1q
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
424B4
25dqv9 oewb
21 May 20
Prospectus supplement with pricing info
6:04am
8-K
EX-99.1
oidgjp1vw
14 May 20
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
8:12am
8-K
EX-99.1
0segmkjfphd1 bu5g46
29 Apr 20
Windtree Therapeutics Announces Reverse Stock Split
5:29pm
8-K
EX-99.1
vupp3
3 Apr 20
Windtree Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Key Business Updates
6:31am